Once completed in the third quarter of 2010, the US$3.2 million factory will turn out high-quality pharmaceutical products for cancer, diabetes, hypertension, and heart disease treatment. 

The factory is part of an investment and technological transfer cooperation agreement signed between Danapha and AQP. Danapha is the parent company of the joint venture, holding 51 percent of its stake, while the US partner possesses 24 percent and the Vietnam Pharmaceutical Corp (Vinapharm) owns 25 percent.